Biohaven Ltd reports results for the quarter ended June 30 - Earnings Summary

• Biohaven Ltd BHVN.N reported a quarterly adjusted loss of $1.94​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.64. The mean expectation of fifteen analysts for the quarter was for a loss of $1.89 per share. Wall Street expected results to range from $-2.32 to $-1.36 per share.

• Reported revenue was zero​; analysts expected zero.

• Biohaven Ltd's reported EPS for the quarter was a loss of $1.94​.

• The company reported a quarterly loss of $198.15 million.

• Biohaven Ltd shares had risen by 4.5% this quarter and lost 60.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Biohaven Ltd is $52.00, about 74.2% above its last closing price of $13.41

This summary was machine generated from LSEG data August 11 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)